Aktis Oncology (AKTS) Expected to Release Earnings on Monday

Posted by on Aug 3rd, 2026

Aktis Oncology (NASDAQ:AKTS – Get Free Report) is projected to release its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect Aktis Oncology to announce earnings of ($0.44) per share and revenue of $2.1430 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Aktis Oncology (NASDAQ:AKTS – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The technology company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). The business had revenue of $3.23 million for the quarter, compared to analysts’ expectations of $2.23 million. On average, analysts expect Aktis Oncology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Aktis Oncology Price Performance

NASDAQ AKTS opened at $22.92 on Monday. The company’s fifty day moving average is $24.25 and its two-hundred day moving average is $20.94. Aktis Oncology has a 52-week low of $14.72 and a 52-week high of $34.19. The firm has a market capitalization of $1.22 billion and a price-to-earnings ratio of -60.32.

Wall Street Analysts Forecast Growth

AKTS has been the subject of several research reports. William Blair started coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating for the company. Wall Street Zen downgraded Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Weiss Ratings raised Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. HC Wainwright boosted their price objective on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. Finally, Raymond James Financial started coverage on Aktis Oncology in a research note on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.60.

Read Our Latest Stock Report on AKTS

Insiders Place Their Bets

In related news, Director Ken Herrmann sold 4,856 shares of the company’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $24.56, for a total value of $119,263.36. Following the sale, the director owned 3,506 shares of the company’s stock, valued at $86,107.36. The trade was a 58.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.30% of the stock is currently owned by insiders.

About Aktis Oncology

(Get Free Report)

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.

Featured Articles

Earnings History for Aktis Oncology (NASDAQ:AKTS)

Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.